The company’s first product is called CardioAI®, which uses machine learning to automatically annotate and interpret electrocardiograms captured and recorded by any legally marketed source. This software medical device enables unattended cardiac monitoring with a seamless EHR interface. The cloud-based solution is scheduled to be released in September 2017, with a full version release slated for N
ovember 2017. The software’s key value is the ability to accurately process and analyze ECG data more quickly than humans can currently do it, with process times for a single 24-hours ECG hovering in the 30-second range. This feature allows for real-time monitoring and analysis of patients with heart conditions, which can provide physicians and caregivers an additional tool to manage chronic conditions and reduce non-essential hospitalizations. The company's vision is to tackle health problems using cutting-edge advances in artificial intelligence.
